Effect of coenzyme Q10 supplement to decrease cardiac complications in ß-Thalassemia major patients

Effect of coenzyme Q10 supplement to decrease cardiac complications predictor factors in ß-Thalassemia major patients

Status

Recruiting

Phases

Phase 3

Study type

Interventional

Source

IRCT

Registry ID

IRCT20221211056777N4

Enrollment

Registered

2024-04-03

Start date

2024-04-06

Completion date

Unknown

Last updated

2024-05-27

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Beta Thalassemia major. Beta thalassemia

Interventions

50 individuals with major thalassemia will be selected. Laboratory parameters (Troponin, D-dimer, Nt-proBNP, EF, PAP) will be examined initially and recorded along with demographic information in a ch

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Beta Thalassemia major Informed consent to participate in the intervention No history of underlying disease Not to use other supplements

Exclusion criteria

Exclusion criteria: Pregnancy or breastfeeding

Design outcomes

Primary

Measure	Time frame
Blood quantitative Troponin level. Timepoint: Before the intervention and eight weeks after the intervention. Method of measurement: Biochemical laboratory kit.;Blood N-terminal prohormone of brain natriuretic peptide (Nt-proBNP) level. Timepoint: Before the intervention and eight weeks after the intervention. Method of measurement: Biochemical laboratory kit.;Blood D-dimer level. Timepoint: Before the intervention and eight weeks after the intervention. Method of measurement: Biochemical laboratory kit.;Cardiac ejection fraction (EF). Timepoint: Before the intervention and eight weeks after the intervention. Method of measurement: Echocardiography.;Pulmonary artery pressure (PAP). Timepoint: Before the intervention and eight weeks after the intervention. Method of measurement: Echocardiography.;Left ventricle end diastolic diameter (LVDD). Timepoint: Before the intervention and eight weeks after the intervention. Method of measurement: Echocardiography.;Left ventricle end systolic diameter (LVDS). Timepoint: Before the intervention and eight weeks after the intervention. Method of measurement: Echocardiography.;Pulsed wave (PW). Timepoint: Before the intervention and eight weeks after the intervention. Method of measurement: Echocardiography.;Interventricular septum thickness (IVSd). Timepoint: Before the intervention and eight weeks after the intervention. Method of measurement: Echocardiography.;Left atrium diameter (LA). Timepoint: Before the intervention and eight weeks after the intervention. Method of measurement: Echocardiography.;Aorta diameter (Ao). Timepoint: Before the intervention and eight weeks after the intervention. Method of measurement: Echocardiography.;Right ventricular dysfunction (RVD). Timepoint: Before the intervention and eight weeks after the intervention. Method of measurement: Echocardiography.;Right ventricular peak systolic myocardial velocity (RVSm). Timepoint: Before the intervention and eight weeks after the intervention. Method of	—

Measure

Time frame

Blood quantitative Troponin level. Timepoint: Before the intervention and eight weeks after the intervention. Method of measurement: Biochemical laboratory kit.;Blood N-terminal prohormone of brain natriuretic peptide (Nt-proBNP) level. Timepoint: Before the intervention and eight weeks after the intervention. Method of measurement: Biochemical laboratory kit.;Blood D-dimer level. Timepoint: Before the intervention and eight weeks after the intervention. Method of measurement: Biochemical laboratory kit.;Cardiac ejection fraction (EF). Timepoint: Before the intervention and eight weeks after the intervention. Method of measurement: Echocardiography.;Pulmonary artery pressure (PAP). Timepoint: Before the intervention and eight weeks after the intervention. Method of measurement: Echocardiography.;Left ventricle end diastolic diameter (LVDD). Timepoint: Before the intervention and eight weeks after the intervention. Method of measurement: Echocardiography.;Left ventricle end systolic diameter (LVDS). Timepoint: Before the intervention and eight weeks after the intervention. Method of measurement: Echocardiography.;Pulsed wave (PW). Timepoint: Before the intervention and eight weeks after the intervention. Method of measurement: Echocardiography.;Interventricular septum thickness (IVSd). Timepoint: Before the intervention and eight weeks after the intervention. Method of measurement: Echocardiography.;Left atrium diameter (LA). Timepoint: Before the intervention and eight weeks after the intervention. Method of measurement: Echocardiography.;Aorta diameter (Ao). Timepoint: Before the intervention and eight weeks after the intervention. Method of measurement: Echocardiography.;Right ventricular dysfunction (RVD). Timepoint: Before the intervention and eight weeks after the intervention. Method of measurement: Echocardiography.;Right ventricular peak systolic myocardial velocity (RVSm). Timepoint: Before the intervention and eight weeks after the intervention. Method of

—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactNima Asgar dehkordi

Shahre-kord University of Medical Sciences

nimanimanimana@gmail.com+98 38 3333 7728

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026